attempted to introduce new therapies based on Th17 lymphocytes which produce IL-17A, IL-17F, IL-21, IL-22, IL-26, IL-6, TNF-α and suppress tumour progression through enhanced antitumor immunity in OC (29). This evidence concerns the gene IL22 and neoplasm.